

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 November 2011 (10.11.2011)

PCT

(10) International Publication Number
WO 2011/138380 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 31/522 (2006.01)
A61K 31/4439 (2006.01) A61P 5/48 (2006.01)

(21) International Application Number:

PCT/EP2011/057163

(22) International Filing Date:

4 May 2011 (04.05.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10162067.2 5 May 2010 (05.05.2010) EP
11164203.9 28 April 2011 (28.04.2011) EP

(71) Applicant (for all designated States except US):

BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHNEIDER, Peter** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **NEUHAUS, Thorsten** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(74) Agents: **HAMMANN, Heinz** et al.; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL FORMULATIONS COMPRISING PIOGLITAZONE AND LINAGLIPTIN

(57) Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases.



WO 2011/138380 A1

PHARMACEUTICAL FORMULATIONS COMPRISING PIOGLITAZONE AND LINAGLIPTIN

5 The present invention relates to pharmaceutical compositions comprising a fixed dose combination (FDC) of a DPP-4 inhibitor drug and pioglitazone (particularly pioglitazone hydrochloride), processes for the preparation thereof, and their use to treat certain diseases.

10 In a more detailed aspect, the present invention relates to a pharmaceutical composition, particularly a solid preparation (e.g. an oral solid dosage form) of a selected dipeptidyl peptidase-4 (DPP-4) inhibitor (particularly linagliptin) and pioglitazone (particularly pioglitazone hydrochloride).

15 In a further more detailed aspect, the present invention relates to a pharmaceutical composition, particularly a solid preparation (e.g. an oral solid dosage form, such as e.g. a tablet, particularly for immediate drug release), comprising a first composition comprising pioglitazone (particularly pioglitazone hydrochloride) and one or more excipients, and a second composition comprising a selected dipeptidyl peptidase-4 (DPP-4) inhibitor (particularly linagliptin) and one or more excipients.

20 In a yet further more detailed aspect, the present invention relates to a pharmaceutical composition, particularly a solid preparation (e.g. an oral solid dosage form, such as e.g. a tablet, particularly for immediate drug release), comprising the following first and second components or parts:

25 the first component or part comprising pioglitazone (particularly pioglitazone hydrochloride) and one or more excipients, the second component or part comprising a selected dipeptidyl peptidase-4 (DPP-4) inhibitor (particularly linagliptin) and one or more excipients.

30 An aim of the present invention is to provide a pharmaceutical composition comprising a combination of a selected DPP-4 inhibitor (particularly linagliptin) and pioglitazone (particularly pioglitazone hydrochloride).

35 A further aim of the present invention is to provide a pharmaceutical composition comprising a selected DPP-4 inhibitor (particularly linagliptin) and/or pioglitazone hydrochloride by which undesired interactions or incompatibilities between any components, e.g. incompatibilities of any of the active ingredients with certain excipients (which may result in significant

- 2 -

degradation of one or both active ingredients and/or which may result in inadequate chemical and/or physical stability of the composition, such as e.g. time-course decomposition of active ingredients, decreased activity, degraded storage or dissolution stability such as time-course changes in the active ingredient dissolution) can be overcome.

5

A further aim of the present invention is to provide a pharmaceutical composition comprising a selected DPP-4 inhibitor (particularly linagliptin) and pioglitazone hydrochloride by which incompatibilities of the active ingredients with one another (which may result in significant degradation of one or both of the active ingredients and/or which may result in inadequate chemical and/or physical stability of the composition, such as e.g. time-course decomposition of active ingredients, decreased activity, degraded storage or dissolution stability such as time-course changes in the active ingredient dissolution) can be overcome.

10

A further aim of the present invention is to provide a pharmaceutical composition comprising linagliptin and pioglitazone hydrochloride which shows no signs or only marginal signs of change, incompatibility or degradation of linagliptin and/or pioglitazone hydrochloride and thus enables a sufficient physical and/or chemical stability, shelf life and/or dissolution profile.

15

A further aim of the invention is to provide a pharmaceutical composition comprising linagliptin and pioglitazone hydrochloride which has high content uniformity and/or which allows an effective production with regard to time and costs of pharmaceutical dosage forms.

20

A further aim of the invention is to provide a pharmaceutical dosage form (particularly for oral administration) comprising linagliptin and pioglitazone hydrochloride which has good chemical and/or physical stability, which has a good shelf life, which has a short disintegration time, which has good dissolution properties and/or which enables a high bioavailability of the active ingredients in a patient.

25

A further aim of the invention is to provide a pharmaceutical dosage form (particularly for oral administration) comprising linagliptin and pioglitazone hydrochloride which is sufficiently (chemically and/or physically) stable, which displays similarity of immediate drug release and/or of in-vitro dissolution profiles and/or is bioequivalent to the free combination and/or which maintains the original dissolution profiles of corresponding mono tablets of each of the individual entity drug products (linagliptin and pioglitazone (e.g. Actos) or pioglitazone mono or combination market tablets).

30
35

- 3 -

Further aims of the present invention become apparent to the one skilled in the art by the description hereinbefore and in the following (including the examples).

- 5 The enzyme DPP-4 also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-4 inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the improvement of glycemic control and for the treatment of diabetes mellitus,
10 particularly in type 2 diabetes patients.

For example, DPP-4 inhibitors and their uses, particularly their uses in metabolic (especially diabetic) diseases, are disclosed in WO 2002/068420, WO 2004/018467, WO 2004/018468, WO 2004/018469, WO 2004/041820, WO 2004/046148, WO 2005/051950, WO
15 2005/082906, WO 2005/063750, WO 2005/085246, WO 2006/027204, WO 2006/029769 or WO2007/014886; or in WO 2004/050658, WO 2004/111051, WO 2005/058901 or WO 2005/097798; or in WO 2006/068163, WO 2007/071738 or WO 2008/017670; or in WO 2007/128721, WO 2007/128724 or WO 2007/128761, or WO 2009/121945.

- 20 A DPP-4 inhibitor within the meaning of the present invention includes, without being limited to, any of those DPP-4 inhibitors mentioned hereinabove and hereinbelow, preferably orally active DPP-4 inhibitors.

In a closer embodiment, a DPP-4 inhibitor within the meaning of the present invention
25 includes a DPP-4 inhibitor with an amino group, especially a free or primary amino group.

In a yet closer embodiment, a DPP-4 inhibitor in the context of the present invention is a DPP-4 inhibitor with a primary amino group, particularly with a free primary amino group.

- 30 In a particularly preferred embodiment of this invention the DPP-4 inhibitor is linagliptin (also named BI 1356).

In attempts to prepare pharmaceutical compositions of selected DPP-4 inhibitors it has been observed, that the DPP-4 inhibitors with a primary or secondary amino group show
35 incompatibilities, degradation problems, or extraction problems with a number of customary

- 4 -

excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines, polyethylene glycol 400. Though the compounds themselves are very stable, they react with incompatible partner drug, or its impurity product, and/or with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios. The amino group appears to react with reducing sugars and with other reactive carbonyl groups and with carboxylic acid functional groups formed for example at the surface of microcrystalline cellulose by oxidation. These difficulties may be primarily observed in low dosage ranges of the DPP-4 inhibitor used, which are required due to their surprising potency, and/or high dosage ranges of the partner drug used.

Further, the DPP-4 inhibitors which have a primary or secondary amino group may show incompatibilities with pioglitazone hydrochloride (which may act as proton donator to the amino group), especially in tight contact provided in tablets and/or in the presence of water and/or under application of compaction forces. The incompatibilities of these DPP-4 inhibitors with pioglitazone hydrochloride can lead to chemical instability, disproportionation of pioglitazone hydrochloride and/or degradation of the DPP-4 inhibitors in the presence of pioglitazone hydrochloride with the consequence of compromised physical stability of the composition.

One stabilizing principle for such compositions may be the use of a stabilizer such as L-arginine. However, prototype tablets which comprise linagliptin, pioglitazone hydrochloride and L-arginine as stabilizer show indeed good (chemical) stability against drug degradation, but at higher moisture conditions (e.g. r.h. > 62%) such tablets show physical instability and tablet core damages, presumably due to interaction with the excipients.

Further, pioglitazone hydrochloride is practically insoluble in water. Particularly, pioglitazone hydrochloride shows very poor solubility in weak acidic and neutral to basic media while it shows slightly better solubility in strongly acidic media. For pioglitazone hydrochloride the intrinsic dissolution rates in aqueous media are only above 1000 $\mu\text{g}/\text{cm}^2/\text{min}$ at pH 1, whereas for less acidic solutions (e.g. pH 2) the intrinsic dissolution rates are below 100 $\mu\text{g}/\text{cm}^2/\text{min}$. Therefore, the intrinsic dissolution rate of pioglitazone hydrochloride may be rate limiting for dissolution/absorption of the composition and pose an additional risk for providing similar dissolution profiles of pioglitazone hydrochloride in the composition to the original

- 5 -

mono tablets (e.g. Actos) or combination market tablets (e.g. Duetact, Competact) and/or for matching bioequivalence with the original mono or combination market tablets.

5 Further, it is another goal to choose, if possible, the excipients for use together with the DPP-4 inhibitor (particularly linagliptin) possibly similar to those for use together with pioglitazone hydrochloride, e.g. in order to minimize stability risks and/or to optimize adhesion of layers or components, if the active ingredients are present in different layers or components.

10 Therefore, pharmaceutical compositions are required to overcome and solve these technical problems.

15 It has now been found that the pharmaceutical compositions, formulations, preparations and dosage forms which are described in greater details herein, have surprising and particularly advantageous properties, which make them particularly suitable for the purposes and aims of this invention.

Thus, the present invention relates to a pharmaceutical composition comprising or made of
a) a first composition, ingredient, component or part comprising or made of pioglitazone or a pharmaceutically acceptable salt thereof, and, optionally, one or more excipients;
20 b) a second composition, ingredient, component or part comprising or made of a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof, and, optionally, one or more excipients;
and, optionally, one or more excipients.

25 In one aspect, it has been found that by individually preparing the first part (composition) containing pioglitazone hydrochloride and one or more excipients, and the second part (composition) containing the DPP-4 inhibitor (particularly linagliptin) and one or more excipients, and forming a composition (solid preparation) containing these two parts, an adverse influence (e.g. degradation, inadequate chemical and/or physical stability, such as
30 e.g. initial or time-course decomposition of active ingredients, decreased activity, degraded storage or dissolution stability such as time-course changes in the active ingredient dissolution) caused by the interaction of the active ingredients with one another and/or with certain excipients of the other part can be suppressed and the dissolution rate of each active ingredient can be optimized.

35

- 6 -

Preferably, within the compositions according to this invention, pioglitazone hydrochloride and the DPP-4 inhibitor (particularly linagliptin) are separated (preferably physically separated) from each other and/or the contact area of the two portions is reduced or minimized, such as e.g. in form of a bilayer tablet (for example, wherein the first layer
5 comprises the first portion and the second layer comprises the second portion).

The present invention further relates to a pharmaceutical composition comprising:

- (1) a first part or composition comprising pioglitazone or a pharmaceutically acceptable salt thereof, and one or more excipients;
- 10 (2) a second part or composition comprising a DPP-4 inhibitor or a pharmaceutically acceptable salt thereof, and one or more excipients.

The present invention further relates to a pharmaceutical composition, particularly for oral administration, comprising the following first and second parts:

- 15 (1) the first part comprising pioglitazone or a pharmaceutically acceptable salt thereof, and one or more excipients;
- (2) the second part comprising a DPP-4 inhibitor, particularly linagliptin, or a pharmaceutically acceptable salt thereof, and one or more excipients.

20 Particularly, the present invention relates to a pharmaceutical composition (e.g. solid preparation or solid oral dosage form, e.g. tablet, particularly for immediate release) comprising the following first and second parts:

- (1) the first part comprising or made of pioglitazone hydrochloride, and one or more excipients;
- 25 (2) the second part comprising or made of linagliptin, and one or more excipients.

In general, excipients which may be used may typically be selected from the group consisting of one or more diluents or fillers, one or more binders, one or more disintegrants, one or more lubricants, and the like.

30

Optionally, excipients which may be used may comprise one or more further additives conventionally used in the field of pharmaceutical preparation, such as e.g. excipients other than those described before, for example colorants, pH adjusting agents, stabilizers, surfactants, flavors, glidants, coating bases and/or coating additives and the like.

35

- 7 -

Preferably the excipients used are pharmaceutically acceptable and may be selected from those conventionally employed in the field of pharmaceutical preparation. In the following the excipients and carriers in the pharmaceutical compositions, formulations, preparations, parts and dosage forms of this invention are described in further detail.

5

The first and second parts in the solid composition of the present invention mean compositions or constitution components, which each may be capable of existing as an independent composition. Thus, each part may be an individual aspect of the invention.

10 (1) First part:

The first part in the present invention is a part (composition, particularly solid composition, e.g. a solid pharmaceutical composition for oral administration) comprising pioglitazone or a pharmaceutically acceptable salt thereof (particularly pioglitazone hydrochloride) and one or more excipients.

15

Excipients of the first part may comprise one or more diluents.

Furthermore, excipients of the first part may comprise one or more diluents and one or more binders.

20

Furthermore, excipients of the first part may comprise one or more diluents, one or more binders and one or more disintegrants.

Furthermore, excipients of the first part may comprise one or more diluents, one or more binders, one or more disintegrants and one or more lubricants.

Furthermore, excipients of the first part may comprise one or more diluents, one or more binders, one or more disintegrants, one or more lubricants and optional further excipient(s).

25

Excipients of the first part may be particularly selected from the group consisting of one or more diluents, one or more binders, one or more disintegrants, and one or more lubricants.

30

Examples of diluents of the first part include, without being limited to, mannitol, microcrystalline cellulose and/or pregelatinized starch. Of these, a particular diluent is mannitol.

35

Examples of binders of the first part include, without being limited to, copovidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose and/or maize starch. Of these, copovidone is preferred.

- 8 -

Examples of disintegrants of the first part include, without being limited to, crospovidone, croscarmellose sodium, microcrystalline cellulose, pregelatinized starch and/or sodium starch glycolate. Of these, crospovidone is preferred.

5

Examples of lubricants of the first part include, without being limited to, sodium stearyl fumarate and/or magnesium stearate. Of these, sodium stearyl fumarate is preferred

10

It has surprisingly been observed that the use of sodium stearyl fumarate as lubricant in the first part results in a faster and more reproducible dissolution rate compared to tablets manufactured with magnesium stearate.

15

In more detail, the first part comprises usually one or more diluents (e.g. microcrystalline cellulose, pregelatinized starch and/or, particularly, mannitol), a binder (e.g. copovidone), a disintegrant (e.g. crospovidone), and a lubricant (e.g. sodium stearyl fumarate).

20

Suitably the pharmaceutical excipients used within the first part of the composition of this invention are conventional materials, such as e.g. mannitol (e.g. D-mannitol) as first diluent, microcrystalline cellulose or pregelatinized starch as second diluent, copovidone as binder, crospovidone as disintegrant, and/or sodium stearyl fumarate as lubricant,

The first part in the present invention may comprise pioglitazone hydrochloride, a first diluent and a second diluent.

25

Furthermore, the first part in the present invention may comprise pioglitazone hydrochloride, a first diluent, a second diluent and a binder.

Furthermore, the first part in the present invention may comprise pioglitazone hydrochloride, a first diluent, a second diluent, a binder and a disintegrant.

Furthermore, the first part in the present invention may comprise pioglitazone hydrochloride, a first diluent, a second diluent, a binder, a disintegrant and a lubricant.

30

Furthermore, the first part in the present invention may comprise pioglitazone hydrochloride, a first diluent, a second diluent, a binder, a disintegrant, a lubricant and optional one or more further ingredients.

35

For example, the first part in the present invention comprises pioglitazone hydrochloride, a first diluent, a second diluent, a binder, a disintegrant and a lubricant.

Preferably, the first part in the present invention is a part (composition) comprising or made of pioglitazone hydrochloride, one first diluent, one second diluent, one binder, one disintegrant and one lubricant.

5

The above-mentioned excipients of the first part (composition) typically comprises mannitol (e.g. D-mannitol) as a diluent or filler.

10

Further, the above-mentioned excipients of the first part (composition) typically comprises mannitol (e.g. D-mannitol) as first diluent.

Further, the above-mentioned excipients of the first part (composition) typically comprises the first diluent mannitol and one second diluent (e.g. microcrystalline cellulose or pregelatinized starch).

15

Further, the above-mentioned excipients of the first part (composition) typically comprises copovidone (also known as copolyvidone or Kollidon VA64) as binder.

20

Further, the above-mentioned excipients of the first part (composition) typically comprises crospovidone (also known as Kollidon CL-SF) as disintegrant.

Further, the above-mentioned excipients of the first part (composition) typically comprises sodium stearyl fumarate as lubricant or anti-adhesive.

25

A typical first part (composition) in the present invention contains or is made of pioglitazone hydrochloride, the first diluent mannitol, the second diluent microcrystalline cellulose or pregelatinized starch, the binder copovidone, the disintegrant crospovidone, and the lubricant sodium stearyl fumarate.

30

In one embodiment [embodiment A], the first part (composition) in the present invention comprises pioglitazone hydrochloride, the first diluent mannitol, the second diluent microcrystalline cellulose, the binder copovidone, the disintegrant crospovidone, and the lubricant sodium stearyl fumarate.

- 10 -

In another embodiment [embodiment B], the first part (composition) in the present invention comprises pioglitazone hydrochloride, the first diluent mannitol, the second diluent pregelatinized starch, the binder copovidone, the disintegrant crospovidone, and the lubricant sodium stearyl fumarate.

5

Among before-mentioned embodiments A and B, embodiment A is preferred.

Accordingly, in one embodiment of the present invention, the first part (composition) in the present invention comprises pioglitazone hydrochloride, a first diluent which is mannitol, a
10 second diluent which is microcrystalline cellulose, a binder which is copovidone, a disintegrant which is crospovidone, and a lubricant which is sodium stearyl fumarate.

In another embodiment of the present invention, the first part (composition) in the present invention consists essentially of: pioglitazone hydrochloride, a first diluent which is mannitol,
15 a second diluent which is microcrystalline cellulose, a binder which is copovidone, a disintegrant which is crospovidone, and a lubricant which is sodium stearyl fumarate.

In another embodiment of the present invention, the first part (composition) in the present invention consists essentially of: pioglitazone hydrochloride, a first diluent which is mannitol,
20 a second diluent which is pregelatinized starch, a binder which is copovidone, a disintegrant which is crospovidone, and a lubricant which is sodium stearyl fumarate.

The content of the pioglitazone or a pharmaceutically acceptable salt thereof (particularly pioglitazone hydrochloride) may be 0.1-60 parts by weight, or 1-50 parts by weight,
25 preferably 2-40 parts by weight, more preferably 5-30 parts by weight or, even more preferably, 5-20 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

The compositions of this invention may contain the active ingredient pioglitazone or a
30 pharmaceutically acceptable salt thereof (particularly pioglitazone hydrochloride) in the dosage range 1-100 mg, or 7.5-60 mg, or 15-60 mg, or 7.5-45 mg, each calculated for the active moiety pioglitazone (free form). Preferred dosages of pioglitazone are 15 mg, 30 mg and 45 mg of pioglitazone (corresponding to 16.53 mg, 33.06 mg and, respectively, 49.59 mg of pioglitazone hydrochloride). Preferably, the equivalent amount of pioglitazone

- 11 -

hydrochloride to the pioglitazone free form is used in the compositions, namely, 16.53 mg, 33.06 mg and, respectively, 49.59 mg of pioglitazone hydrochloride.

5 The content of the first diluent (particularly mannitol) may be 5-99 parts by weight, or 10-95 parts by weight, preferably 20-90 parts by weight, more preferably 40-80 parts by weight or, even more preferably, 50-70 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

10 The content of the second diluent (e.g. microcrystalline cellulose or pregelatinized starch) may be 1-70 parts by weight, or 1-50 parts by weight, preferably 5-40 parts by weight, more preferably 10-30 parts by weight or, even more preferably, 20-25 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

15 The content of the binder (e.g. copovidone) may be 0.1-30 parts by weight, or 0.5-20 parts by weight, preferably 1-10 parts by weight, more preferably 1-5 parts by weight or, even more preferably, 1-3 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

20 The content of the disintegrant (e.g. crospovidone) may be 0.1-30 parts by weight, or 0.5-20 parts by weight, preferably 1-10 parts by weight, more preferably 1-5 parts by weight or, even more preferably, 1-3 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

25 The content of the lubricant (e.g. sodium stearyl fumarate) may be 0.5-20 parts by weight, or 0.1-10 parts by weight, preferably 0.1-4 parts by weight, more preferably 0.5-3 parts by weight or, even more preferably, 1-3 parts by weight, relative to 100 parts by weight of the above-mentioned first part.

30 In a further embodiment, the amount of sodium stearyl fumarate is preferably ≥ 1 % by weight of the above-mentioned first part, e.g. 1-3% or 1-2%, more preferably ≥ 1.2 %, e.g. from 1.2 % to 2 %, most preferably about 2%, by weight of the above-mentioned first part.

35 The weight ratio of the pioglitazone or a pharmaceutically acceptable salt thereof (particularly pioglitazone hydrochloride) relative to the first diluent (particularly mannitol) may be (pioglitazone or a salt thereof:first diluent) 0.001-30:1, preferably 0.005-10:1, more preferably

- 12 -

0.01-1:1; or, even more preferably, 0.1-0.5:1 of pioglitazone hydrochloride:mannitol (e.g. about 0.14-0.15:1 or about 0.33:1).

5 The weight ratio of the pioglitazone or a pharmaceutically acceptable salt thereof (particularly pioglitazone hydrochloride) relative to the first and second diluent (particularly mannitol and either microcrystalline cellulose or pregelatinized starch) may be 0.001-30:1 (pioglitazone or a salt thereof:first and second diluent), preferably 0.005-10:1, more preferably 0.01-1:1; or, even more preferably, 0.05-0.5:1 of pioglitazone hydrochloride:sum of mannitol and either microcrystalline cellulose or pregelatinized starch (e.g. about 0.11:1 or about 0.24:1).

10

The weight ratio of the first diluent (particularly mannitol) relative to the second diluent (particularly either microcrystalline cellulose or pregelatinized starch) may be preferably from 2.22:1 to 4.33:1 (first diluent:second diluent), more preferably about 2.78:1 or about 3.24:1.

15 The first part (composition) according to this invention may comprise one or more of the following:

2-40 % pioglitazone (particularly pioglitazone hydrochloride),

40-90 % one or more diluents,

0.5-20 % one or more binders,

20 0.5-20 % one or more disintegrants, and

0.1-4 % one or more lubricants,

wherein the percentages are by weight of the total first part.

The following ranges are preferred:

25 5-30 % pioglitazone (particularly pioglitazone hydrochloride),

40-80 % diluent 1,

5-40 % diluent 2,

1-10 % binder,

1-10 % disintegrant,

30 0.5-3 % lubricant,

wherein the percentages are by weight of the total first part.

The following ranges are more preferred:

5-20 % pioglitazone (particularly pioglitazone hydrochloride),

35 50-70 % diluent 1,

- 13 -

10-30 % diluent 2,
1-3 % binder,
1-3 % disintegrant,
1-3 % lubricant,

5 wherein the percentages are by weight of the total first part.

In a particular embodiment, the first part (composition) may comprise:

an intragranular portion containing pioglitazone hydrochloride, a first diluent (particularly mannitol), partly a second diluent (particularly microcrystalline cellulose), and a binder
10 (particularly copovidone); and

an extragranular portion containing a disintegrant (particularly crospovidone), a lubricant (particularly sodium stearyl fumarate), and partly a second diluent (particularly microcrystalline cellulose).

15 In another embodiment of the present invention, the first part (composition) in the present invention consists essentially of:

an intragranular portion containing pioglitazone hydrochloride, a first diluent which is mannitol, a part of a second diluent which is microcrystalline cellulose, and a binder which is copovidone; and

20 an extragranular portion containing a disintegrant which is crospovidone, the remaining part of the second diluent which is microcrystalline cellulose, and a lubricant which is sodium stearyl fumarate.

To prepare the pioglitazone-containing first part (composition) of this invention a granulate
25 can be prepared e.g. by a wet granulation process. Alternative methods for granulation of the active ingredient and excipients with a granulation liquid are fluid bed granulation or one pot granulation.

In the wet granulation process the granulation liquid is a solvent such as water, ethanol,
30 methanol, isopropanol, acetone, or a mixture thereof, preferably purified water, and contains a binder such as copovidone. The solvent is a volatile component, which does not remain in the final product. The active ingredient pioglitazone HCl and the other excipients (e.g. mannitol and microcrystalline cellulose) with exception of the lubricant (e.g. sodium stearyl fumarate) and of the disintegrant (e.g. crospovidone) are premixed and granulated with the
35 aqueous granulation liquid, e.g. using a high shear granulator. The wet granulation step is

- 14 -

followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying. The dried granules are sieved through an appropriate sieve to give the pioglitazone granulate. After dry sieving the granulate is optionally blended in a suitable blender. The lubricant (e.g. sodium stearyl fumarate) and the disintegrant (e.g. crospovidone) are blended in a suitable conventional blender such as a free fall blender to give a pre-mix, the pre-mix is sieved, and final mixed with the pioglitazone granulate in a suitable conventional blender such as a free fall blender to give the pioglitazone final blend.

- 5
- 10 Alternatively, but less preferred, in the wet granulation process the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, or a mixture thereof, preferably purified water, and contains a binder, such as copovidone, and a part of the second diluent (e.g. microcrystalline cellulose). The solvent is a volatile component, which does not remain in the final product. The active ingredient pioglitazone HCl and the other
- 15 excipients (e.g. mannitol, remaining part of microcrystalline cellulose) with exception of the lubricant (e.g. sodium stearyl fumarate) and of the disintegrant (e.g. crospovidone) are premixed and granulated with the aqueous granulation liquid, e.g. using a high shear granulator. The wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying. The
- 20 dried granules are sieved through an appropriate sieve to give the pioglitazone granulate. After dry sieving the granulate is optionally blended in a suitable blender. The lubricant (e.g. sodium stearyl fumarate) and the disintegrant (e.g. crospovidone) are blended in a suitable conventional blender such as a free fall blender to give a pre-mix, the pre-mix is sieved, and final mixed with the pioglitazone granulate in a suitable conventional blender such as a free
- 25 fall blender to give the pioglitazone final blend.

In an embodiment, the second diluent (e.g. microcrystalline cellulose) may be optionally used intragranular, extragranular, or as a combination of both.

- 30 In a particular embodiment, one part of the second diluent (e.g. microcrystalline cellulose) may be present in the pioglitazone granulate and the remaining part thereof may be present in the extragranular portion of the pioglitazone final blend. For example, part of the second diluent (e.g. microcrystalline cellulose) may be added extragranular prior to final blending.

- 15 -

The amount of second diluent (e.g. microcrystalline cellulose) being present in the intragranular portion of the first part may be from 0 to 100%, preferably from 10 to 80%, more preferably from 20 to 50%, most preferably from 30 to 40% (e.g. about 34%), of total second diluent amount in the first part.

5

The amount of second diluent (e.g. microcrystalline cellulose) being present in the extragranular portion of the first part may be from 0 to 100%, preferably from 20 to 90%, more preferably from 50 to 80%, most preferably from 60 to 70% (e.g. about 66%), of total second diluent amount in the first part.

10

In an embodiment, the ratio of the intragranular second diluent (e.g. one part of microcrystalline cellulose) to the extragranular second diluent (e.g. remaining part of microcrystalline cellulose) may be from about 1:9 to about 9:1, or from about 1:4 to about 1:1, preferably from about 1:3 to about 1:1, more preferably from about 1:2.5 to about 1.15, even more preferably from about 3:7 to about 4:6, most preferably about 1:2.

15

Preferably, the pioglitazone final blend is prepared as follows: The wet granulation process the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, or a mixture thereof, preferably purified water, and contains a binder, such as copovidone. The solvent is a volatile component, which does not remain in the final product. The active ingredient pioglitazone HCl and the other excipients (e.g. mannitol, a part of the second diluent (e.g. microcrystalline cellulose, such as e.g. from about 20% to 50%, preferably from 30% to 40%, more preferably about one-third of total microcrystalline cellulose of the first part) with exception of the lubricant (e.g. sodium stearyl fumarate) and of the disintegrant (e.g. crospovidone) are premixed and granulated with the aqueous granulation liquid, e.g. using a high shear granulator. The wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying. The dried granules are sieved through an appropriate sieve to give the pioglitazone granulate. After dry sieving the granulate is optionally blended in a suitable blender. The remaining part of the second diluent (e.g. microcrystalline cellulose, pre-screened or unscreened, such as e.g. from about 50% to 80%, preferably from 60% to 70%, more preferably about two-third of total microcrystalline cellulose of the first part), the lubricant (e.g. sodium stearyl fumarate, pre-screened or unscreened) and the disintegrant (e.g. crospovidone, pre-screened or unscreened) are combined with the pioglitazone granulate (screened and optionally blended) for blending (e.g. in a suitable conventional

20

25

30

35

blender such as a free fall blender). The blend is screened to give the pioglitazone final blend.

5 (2) Second part:

The second part in the present invention is a part (composition, particularly solid composition, e.g. a solid pharmaceutical composition for oral administration) comprising linagliptin or a pharmaceutically acceptable salt thereof (particularly linagliptin) and one or more excipients.

10

Excipients of the second part may comprise one or more diluents.

Furthermore, excipients of the second part may comprise one or more diluents and one or more binders.

15 Furthermore, excipients of the second part may comprise one or more diluents, one or more binders and one or more disintegrants.

Furthermore, excipients of the second part may comprise one or more diluents, one or more binders, one or more disintegrants and one or more lubricants.

Furthermore, excipients of the second part may comprise one or more diluents, one or more binders, one or more disintegrants, one or more lubricants and optional further excipient(s).

20

Excipients of the second part may be particularly selected from the group consisting of one or more diluents, one or more binders, one or more disintegrants, and one or more lubricants.

25 Examples of diluents of the second part include, without being limited to, cellulose powder, dibasic calciumphosphate (in particular anhydrous or dibasic calciumphosphate dihydrate), erythritol, low-substituted hydroxypropyl cellulose, mannitol, starch, pregelatinized starch and xylitol. The diluents pre-gelatinized starch and low-substituted hydroxypropyl cellulose show additional binder properties. Among these diluents mannitol and/or pregelatinized starch are
30 preferred.

In case the second part (composition) according to the invention comprises one diluent, then the diluent is preferably mannitol or pregelatinized starch, more preferably mannitol.

- 17 -

Preferably, in case the second part (composition) according to the invention comprises two or more diluents, then the first diluent is preferably mannitol and the second diluent is selected from the group of diluents as described hereinbefore, more preferably pregelatinized starch, which shows additional binder properties.

5

Examples of binders of the second part include, without being limited to, copovidone, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (povidone), pregelatinized starch and low-substituted hydroxypropyl cellulose (L-HPC). Of these, copovidone and/or pregelatinized starch are preferred.

10

The above mentioned binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.

Examples of disintegrants of the second part include, without being limited to, crospovidone, 15 low-substituted hydroxypropyl cellulose (L-HPC) and starches, such as native starches, in particular corn starch, and pregelatinized starch. Of these, corn starch is preferred.

Examples of lubricants of the second part include, without being limited to, talc, polyethylene glycol (particularly polyethylene glycol with a molecular weight in a range from about 4400 to 20 about 9000), hydrogenated castor oil, fatty acid and salts of fatty acids, particularly the calcium, magnesium, sodium or potassium salts thereof, for example calcium behenate, calcium stearate, sodium stearyl fumarate or magnesium stearate. Of these, magnesium stearate is preferred.

25 In more detail, the second part comprises usually one or more diluents (e.g. mannitol and/or pregelatinized starch), a binder (e.g. copovidone), a disintegrant (e.g. corn starch), and a lubricant (e.g. magnesium stearate).

Suitably the pharmaceutical excipients used within the second part of the composition of this 30 invention are conventional materials, such as e.g. mannitol (e.g. D-mannitol) as first diluent, pregelatinized starch as second diluent, copovidone as binder, corn starch as disintegrant, and/or magnesium stearate as lubricant.

The second part in the present invention may comprise linagliptin, a first diluent and a 35 second diluent.

- 18 -

Furthermore, the second part in the present invention may comprise linagliptin, a first diluent, a second diluent and a binder.

Furthermore, the second part in the present invention may comprise linagliptin, a second diluent, a second diluent, a binder and a disintegrant.

5 Furthermore, the second part in the present invention may comprise linagliptin, a second diluent, a second diluent, a binder, a disintegrant and a lubricant.

Furthermore, the second part in the present invention may comprise linagliptin, a first diluent, a second diluent, a binder, a disintegrant, a lubricant and optional one or more further ingredients.

10

For example, the second part in the present invention comprises linagliptin, a first diluent, a second diluent, a binder, a disintegrant and a lubricant.

15 Preferably, the second part in the present invention is a part (composition) comprising or made of linagliptin, one first diluent, one second diluent, one binder, one disintegrant and one lubricant.

The above-mentioned excipients of the second part (composition) typically comprises mannitol (e.g. D-mannitol) as a diluent or filler.

20

Further, the above-mentioned excipients of the second part (composition) typically comprises mannitol (e.g. D-mannitol) as first diluent.

25 Further, the above-mentioned excipients of the second part (composition) typically comprises the first diluent mannitol and one second diluent (e.g. pregelatinized starch).

Further, the above-mentioned excipients of the second part (composition) typically comprises copovidone (also known as copolyvidone or Kollidon VA64) as binder.

30 Further, the above-mentioned excipients of the second part (composition) typically comprises corn starch (e.g. maize starch) as disintegrant.

Further, the above-mentioned excipients of the second part (composition) typically comprises magnesium stearate as lubricant or anti-adhesive.

35

- 19 -

A typical second part (composition) in the present invention contains or is made of linagliptin, the first diluent mannitol, the second diluent pregelatinized starch, the binder copovidone, the disintegrant corn starch, and the lubricant magnesium stearate.

- 5 Accordingly, in one embodiment of the present invention, the second part (composition) comprises linagliptin, a first diluent which is mannitol, a second diluent which is pregelatinized starch, a binder which is copovidone, a disintegrant which is corn starch, and a lubricant which is magnesium stearate.
- 10 In another embodiment of the present invention, the second part (composition) consists essentially of: linagliptin, a first diluent which is mannitol, a second diluent which is pregelatinized starch, a binder which is copovidone, a disintegrant which is corn starch, and a lubricant which is magnesium stearate.
- 15 The compositions of this invention may contain the active ingredient linagliptin in the dosage range 0.1-100 mg. Particular oral dosage strengths of linagliptin are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg. More particular oral dosage strengths of linagliptin within this invention are 2.5 mg and 5 mg. A preferred oral dosage strength of linagliptin is 5 mg.
- 20 The second part (composition) according to this invention may comprise one or more of the following:
- | | |
|-------------|--|
| 0.5-20 % | active pharmaceutical ingredient (particularly linagliptin), |
| 40-90 % | one or more diluents, |
| 0.5-20 % | one or more binders, |
| 25 0.5-20 % | one or more disintegrants, and |
| 0.1-4 % | one or more lubricants, |
- wherein the percentages are by weight of the total second part.

The following ranges are preferred:

- | | |
|-------------|--|
| 30 0.5-10 % | active pharmaceutical ingredient (particularly linagliptin), |
| 50-75 % | diluent 1, |
| 0-15 % | diluent 2, |
| 1-15 % | binder, |
| 1-15 % | disintegrant, |
| 35 0.5-3 % | lubricant, |

- 20 -

wherein the percentages are by weight of the total second part.

The following ranges are more preferred:

- | | | |
|---|---------|--|
| | 0.5-7 % | active pharmaceutical ingredient (particularly linagliptin), |
| 5 | 50-75 % | diluent 1, |
| | 5-15 % | diluent 2, |
| | 2-4 % | binder, |
| | 8-12 % | disintegrant, |
| | 0.5-2 % | lubricant, |
- 10 wherein the percentages are by weight of the total second part.

To prepare the linagliptin-containing second part (composition) of this invention a granulate can be prepared e.g. by a wet granulation process. Alternative methods for granulation of the active ingredient and excipients with a granulation liquid are fluid bed granulation or one pot granulation.

15

In the wet granulation process the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, or a mixture thereof, preferably purified water, and contains a binder such as copovidone. The solvent is a volatile component, which does not remain in the final product. The active ingredient linagliptin and the other excipients (e.g. mannitol, pregelatinized starch and corn starch) with exception of the lubricant (e.g. magnesium stearate) are premixed and granulated with the aqueous granulation liquid, e.g. using a high shear granulator. The wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.

20

25 The dried granules are sieved through an appropriate sieve to give the linagliptin granulate. After dry sieving the granulate is optionally blended in a suitable blender. The lubricant (e.g. magnesium stearate) is final blended with the linagliptin granulate in a suitable conventional blender such as a free fall blender to give the linagliptin final blend.

30 For the preparation of tablets or tablet cores the final blend(s) are compressed into tablets. For the preparation of capsules the final blend(s) may be filled into a capsule.

Preferably, the pioglitazone final blend and the linagliptin final blend are compressed together into bilayer tablet cores, e.g. using a standard bilayer rotary tablet press.

35

- 21 -

Accordingly, a process for the preparation of a pharmaceutical composition according to this invention may further comprise combining or mixing the final blends and compressing into bilayer tablet cores.

5 Depending on the individual weight of each layer of the bilayer tablet core preferably the layer with the larger weight is chosen to be the first layer and the layer with the smaller weight to be the second layer. Less preferably the orientation of layers is the opposite. In case identical tablet layer weights of the first and second layer the more voluminous layer is preferably the first layer and only less preferably the second layer.

10

For the preparation of film-coated tablets a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using standard film coater (such as e.g. a perforated pan coater).

15 The film coating solvent is a volatile component, which does not remain in the final product. A typical film-coat comprises a film coating agent, a plasticizer, a glidant, and optionally one or more pigments and colors. For example, the film coat may comprise hydroxypropylmethylcellulose (HPMC), propylene glycol, talc, titanium dioxide and, optionally, iron oxide (e.g. iron oxide yellow and/or red).

20 Alternatively, for preparing film-coated tablets of this invention the film coating suspension is prepared by using commercially available film coating pre-mixtures such as Opadry™ (which may be identical in qualitative and quantitative composition to using single film excipients). The single ingredients of the film-coat or the commercially available premixture such as Opadry™ is suspended or dissolved in the film coating solvent, preferably purified water at room temperature, for preparing the film-coating suspension.

25

To achieve most optimum physical and chemical stability the film-coating process is performed in such a way that the residual moisture of the final linagliptin/pioglitazone film-coated tablets is in the range of from 0.5 to 2.5%, preferably in the range of from 0.7 to 2.0%, more preferably in the range of from 0.8 to 1.5%, and most preferably in the range of from 30 0.9 to 1.4% by weight.

The term "linagliptin" as employed herein refers to linagliptin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a polymorphic form thereof. Crystalline forms are described in WO 2007/128721. Preferred crystalline forms are the polymorphs A and B 35 described therein. In particular, linagliptin is the free base 1-[(4-methyl-quinazolin-2-


- 22 -

yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine. As linagliptin or a pharmaceutically acceptable salt thereof, linagliptin is preferred. Methods for the manufacture of linagliptin are described in the patent applications WO 2004/018468 and WO 2006/048427 for example.

5 Linagliptin is distinguished from structurally comparable DPP-4 inhibitors, as it combines exceptional potency and a long-lasting effect with favourable pharmacological properties, receptor selectivity and a favourable side-effect profile or bring about unexpected therapeutic advantages or improvements when used in combination with pioglitazone according to this invention.

10

1-[4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine (linagliptin) has the following structural formula:



15 The term “pioglitazone” as employed herein refers to pioglitazone, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a polymorphic form thereof. Preferable examples of the salt of pioglitazone include salts with hydrochloric acid. As pioglitazone or a pharmaceutically acceptable salt thereof, pioglitazone hydrochloride is preferred. A preferred crystalline form of pioglitazone hydrochloride is the crystal form
20 (polymorph) defined as Form I, e.g. in WO 03/026586.

In a preferred embodiment, the pharmaceutical compositions, dosage forms or tablets of this invention contain linagliptin in an amount of 5 mg, and pioglitazone in an amount of 15 mg, 30 mg or 45 mg.

25

In a further embodiment, the pharmaceutical compositions, dosage forms or tablets of this invention contain linagliptin in an amount of 2.5 mg, and pioglitazone in an amount of 15 mg, 30 mg or 45 mg.

30 In the pharmaceutical composition and pharmaceutical dosage form according to the invention the active pharmaceutical ingredients preferably may have a particle size

- 23 -

distribution such that at least 90 % of the respective active pharmaceutical ingredient particles, with regard to the distribution by volume, has a particle size smaller than 200 μm , i.e. $X_{90} < 200 \mu\text{m}$.

5 In particular for use in the pharmaceutical composition and pharmaceutical dosage form according to the invention linagliptin, for example a crystalline form thereof, preferably have a particle size distribution (by volume) such that at least 90 % of the respective active pharmaceutical ingredient has a particle size smaller than 200 μm , i.e. $X_{90} < 200 \mu\text{m}$, more preferably $X_{90} \leq 150 \mu\text{m}$. More preferably the particle size distribution is such that $X_{90} \leq 100$
10 μm , even more preferably $X_{90} \leq 75 \mu\text{m}$. In addition the particle size distribution is preferably such that $X_{90} > 0.1 \mu\text{m}$, more preferably $X_{90} \geq 1 \mu\text{m}$, most preferably $X_{90} \geq 5 \mu\text{m}$. Therefore preferred particle size distributions are such that $0.1 \mu\text{m} < X_{90} < 200 \mu\text{m}$, particularly $0.1 \mu\text{m} < X_{90} \leq 150 \mu\text{m}$, more preferably $1 \mu\text{m} \leq X_{90} \leq 150 \mu\text{m}$, even more preferably $5 \mu\text{m} \leq X_{90} \leq 100 \mu\text{m}$. A preferred example of a particle size distribution of linagliptin is such that $X_{90} \leq 50$
15 μm or $10 \mu\text{m} \leq X_{90} \leq 50 \mu\text{m}$.

Furthermore for use in the pharmaceutical composition and pharmaceutical dosage form according to the invention linagliptin, for example a crystalline form thereof, preferably has a particle size distribution (by volume) such that $X_{50} \leq 90 \mu\text{m}$, more preferably $X_{50} \leq 75 \mu\text{m}$,
20 even more preferably $X_{50} \leq 50 \mu\text{m}$, most preferably $X_{50} \leq 40 \mu\text{m}$. In addition the particle size distribution is preferably such that $X_{50} \geq 0.1 \mu\text{m}$, more preferably $X_{50} \geq 0.5 \mu\text{m}$, even more preferably $X_{50} \geq 4 \mu\text{m}$. Therefore preferred particle size distributions are such that $0.1 \mu\text{m} \leq X_{50} \leq 90 \mu\text{m}$, particularly $0.5 \mu\text{m} \leq X_{50} \leq 75 \mu\text{m}$, more preferably $4 \mu\text{m} \leq X_{50} \leq 75 \mu\text{m}$, even more preferably $4 \mu\text{m} \leq X_{50} \leq 50 \mu\text{m}$. A preferred example is $8 \mu\text{m} \leq X_{50} \leq 40 \mu\text{m}$.

25 Furthermore for use in the pharmaceutical composition and pharmaceutical dosage form according to the invention linagliptin, for example a crystalline form thereof, preferably has a particle size distribution (by volume) such that $X_{10} \geq 0.05 \mu\text{m}$, more preferably $X_{10} \geq 0.1 \mu\text{m}$, even more preferably $X_{10} \geq 0.5 \mu\text{m}$.

30 For use in the pharmaceutical composition and pharmaceutical dosage form according to the invention pioglitazone (particularly pioglitazone hydrochloride), for example a crystalline form thereof, can be unmilled, milled (e.g. with a peg mill) or micronised. Milled pioglitazone hydrochloride may have, in one embodiment, a particle size distribution (by volume) such
35 that at least 90 % of the respective active pharmaceutical ingredient has a particle size

- 24 -

smaller than 100 μm , i.e. $X_{90} < 100 \mu\text{m}$, and, optionally, X_{50} is 20-60 μm , and, further optionally, X_{10} is 5-10 μm . Unmilled pioglitazone hydrochloride may have a particle size distribution (by volume) such that at least 98 % of the respective active pharmaceutical ingredient has a particle size smaller than 250 μm , i.e. $X_{98} < 250 \mu\text{m}$, and, optionally, $X_{90} < 200 \mu\text{m}$ (e.g. 150-190 μm), and, further optionally, $X_{50} < 100 \mu\text{m}$ (e.g. 70-90 μm), and, yet further optionally, X_{10} is 15-20 μm . In another embodiment, the median size of pioglitazone hydrochloride is preferably 1-50 μm , more preferably 2-30 μm , e.g. 2 to 25 μm or 2 to 15 μm (e.g. about 13 μm).

10 In a further embodiment, the following ranges of particle size distribution of pioglitazone HCl are more preferred:

Unmilled pioglitazone hydrochloride may have a particle size distribution (by volume) such that at least 98 % of the respective active pharmaceutical ingredient has a particle size smaller than 450 μm , i.e. $X_{98} < 450 \mu\text{m}$, and, optionally, $X_{90} < 300 \mu\text{m}$ (e.g. $1 \mu\text{m} < X_{90} < 300 \mu\text{m}$), and, further optionally, $X_{50} < 120 \mu\text{m}$ (e.g. $1 \mu\text{m} < X_{50} < 120 \mu\text{m}$), and, yet further optionally, $X_{10} < 50 \mu\text{m}$ (e.g. $0.1 \mu\text{m} < X_{10} < 50 \mu\text{m}$, e.g. 15-20 μm).

Mannitol as mentioned hereinbefore and hereinafter is preferably D-mannitol (preferably of the beta-polymorphic form) and is preferably with a grade with small particle size suitable for (wet) granulation. Preferably, mannitol as mentioned hereinbefore and hereinafter is fine powdered. In the pioglitazone-containing first part (composition) of the invention, the mannitol may be crystalline powder (e.g. Pearlitol 25CTM), milled (e.g. with a peg mill) or of directly compressible grade (e.g. Pearlitol SD200TM). Mannitol of the first part may have a mean particle diameter of about 10 μm to about 180 μm , particularly of about 20 μm to about 40 μm .

Pregelatinized starch as mentioned hereinbefore and hereinafter is preferably a starch (e.g. maize (corn), potato or rice starch) that has been chemically and/or mechanically processed to rupture all or part of the starch granules. Particularly, partially pregelatinized starch has to be mentioned. An example is Starch 1500TM (Colorcon).

Copovidone as mentioned hereinbefore and hereinafter is preferably a copolymerisate of vinylpyrrolidon with vinyl acetate, preferably with a molecular weight from about 45000 to about 70000. An example is Polyvidon VA 64 or KollidonTM VA 64 (BASF).

35

- 25 -

Crospovidone as mentioned hereinbefore and hereinafter is preferably a cross-linked and water insoluble form of PVP. An example is Kollidon™ CL-SF (BASF).

5 An example of sodium stearyl fumarate as mentioned hereinbefore and hereinafter is PRUV™.

Cellulose as mentioned hereinbefore and hereinafter is typically crystalline cellulose, preferably microcrystalline cellulose. An example is MCC 101.

10 Corn starch as mentioned hereinbefore and hereinafter is preferably a native starch. An example is Maize starch (extra white) (Roquette).

The pharmaceutical compositions (or formulations) may be packaged in a variety of ways. Generally, an article for distribution includes a container that contains the pharmaceutical
15 composition in an appropriate form. Tablets are typically packed in an appropriate primary package for easy handling, distribution and storage and for assurance of proper stability of the composition at prolonged contact with the environment during storage. Primary containers for tablets may be bottles or blister packs.

20 A suitable bottle may be made from glass or polymer (preferably polypropylene (PP) or high density polyethylene (HD-PE)) and sealed with a screw cap. The screw cap may be provided with a child resistant safety closure (e.g. press-and-twist closure) for preventing or hampering access to the contents by children. If required (e.g. in regions with high humidity), by the
25 additional use of a desiccant (such as e.g. bentonite clay, molecular sieves, or, preferably, silica gel) the shelf life of the packaged composition can be prolonged.

A suitable blister pack comprises or is formed of a top foil (which is breachable by the tablets) and a bottom part (which contains pockets for the tablets). The top foil may contain a
30 metallic foil, particularly an aluminium or aluminium alloy foil (e.g. having a thickness of 20µm to 45µm, preferably 20µm to 25µm) that is coated with a heat-sealing polymer layer on its inner side (sealing side). The bottom part may contain a multi-layer polymer foil (such as e.g. poly(vinyl choride) (PVC) coated with poly(vinylidene choride) (PVDC); or a PVC foil laminated with poly(chlorotriflouroethylene) (PCTFE)) or a multi-layer polymer-metal-polymer
35 foil (such as e.g. a cold-formable laminated PVC/aluminium/polyamide composition).

- 26 -

To ensure a long storage period especially under hot and wet climate conditions an additional overwrap or pouch made of a multi-layer polymer-metal-polymer foil (e.g. a laminated polyethylen/aluminium/polyester composition) may be used for the blister packs. Supplementary desiccant (such as e.g. bentonite clay, molecular sieves, or, preferably, silica gel) in this pouch package may prolong the shelf life even more under such harsh conditions.

The article may further comprise a label or package insert, which refer to instructions customarily included in commercial packages of therapeutic products, that may contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. In one embodiment, the label or package inserts indicates that the composition can be used for any of the purposes described herein.

The pharmaceutical combinations of pioglitazone and linagliptin according to the present invention are suitable for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus, obesity and conditions related thereto (e.g. diabetic complications), either in type 2 diabetes patients who have not been previously treated with an antihyperglycemic agent, or in type 2 diabetes patients with insufficient glycemic control despite therapy with one or two conventional antihyperglycemic agents selected from metformin, sulphonylureas, thiazolidinediones (e.g. pioglitazone), glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues; optionally in combination with one or more other active substances.

In an embodiment, the present invention relates to the pharmaceutical compositions or combinations of pioglitazone and linagliptin according to this invention for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus, obesity and conditions related thereto (e.g. diabetic complications), in type 2 diabetes patients with insufficient glycemic control despite therapy with pioglitazone alone.

In a further embodiment, the present invention relates to the pharmaceutical compositions or combinations of pioglitazone and linagliptin according to this invention for use in combination

- 27 -

with metformin in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus, obesity and conditions related thereto (e.g. diabetic complications), in type 2 diabetes patients with insufficient glycemic control despite dual combination therapy with pioglitazone and metformin.

In a further embodiment, the present invention relates to the pharmaceutical compositions or combinations of pioglitazone and linagliptin according to this invention for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus, obesity and conditions related thereto (e.g. diabetic complications), in drug-naïve type 2 diabetes patients.

In a further embodiment, the present invention relates to the pharmaceutical compositions or combinations of pioglitazone and linagliptin according to this invention for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus, obesity and conditions related thereto (e.g. diabetic complications), in type 2 diabetes patients for whom metformin therapy is inappropriate, e.g. due to intolerability or contraindication against metformin (e.g. patients at risk of gastrointestinal adverse events or of lactic acidose, such as e.g. renally impaired or elderly patients).

Further, the present invention also relates to the pharmaceutical compositions or combinations of pioglitazone and linagliptin according to this invention for use in one or more of the following methods of

- preventing, slowing the progression of, delaying or treating a metabolic disorder or disease, such as e.g. type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, postabsorptive hyperglycemia, overweight, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertension, atherosclerosis, endothelial dysfunction, osteoporosis, chronic systemic inflammation, non alcoholic fatty liver disease (NAFLD), retinopathy, neuropathy, nephropathy, polycystic ovarian syndrome, and/or metabolic syndrome;
- improving and/or maintaining glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose, of postabsorptive plasma glucose and/or of glycosylated hemoglobin HbA1c;

- 28 -

- preventing, slowing, delaying or reversing progression from pre-diabetes, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus;
 - 5 - preventing, reducing the risk of, slowing the progression of, delaying or treating of complications of diabetes mellitus such as micro- and macrovascular diseases, such as nephropathy, micro- or macroalbuminuria, proteinuria, retinopathy, cataracts, neuropathy, learning or memory impairment, neurodegenerative or cognitive disorders, cardio- or cerebrovascular diseases, tissue ischaemia, diabetic foot or ulcer, atherosclerosis, hypertension, endothelial dysfunction, myocardial infarction, acute coronary syndrome, 10 unstable angina pectoris, stable angina pectoris, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders, vascular restenosis, and/or stroke;
 - reducing body weight and/or body fat or preventing an increase in body weight and/or body fat or facilitating a reduction in body weight and/or body fat;
 - preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or 15 the decline of the functionality of pancreatic beta cells and/or for improving, preserving and/or restoring the functionality of pancreatic beta cells and/or stimulating and/or restoring or protecting the functionality of pancreatic insulin secretion;
 - preventing, slowing, delaying or treating non alcoholic fatty liver disease (NAFLD) including hepatic steatosis, non-alcoholic steatohepatitis (NASH) and/or liver fibrosis 20 (such as e.g. preventing, slowing the progression, delaying, attenuating, treating or reversing hepatic steatosis, (hepatic) inflammation and/or an abnormal accumulation of liver fat);
 - preventing, slowing the progression of, delaying or treating type 2 diabetes with failure to conventional antidiabetic mono- or combination therapy;
 - 25 - achieving a reduction in the dose of conventional antidiabetic medication required for adequate therapeutic effect;
 - reducing the risk for adverse effects associated with conventional antidiabetic medication (e.g. hypoglycemia); and/or
 - maintaining and/or improving the insulin sensitivity and/or for treating or preventing 30 hyperinsulinemia and/or insulin resistance;
- in a patient in need thereof (such as e.g. a patient as described herein, especially a type 2 diabetes patient), optionally in combination with one or more other therapeutic substances (such as e.g. selected from metformin, sulphonylureas, thiazolidinediones, glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues).

35

- 29 -

Further, the present invention also relates to the pharmaceutical compositions or combinations according to this invention for use in type 2 diabetes patients who are with diagnosed renal impairment (e.g. as diagnosed by impaired eGFR and/or impaired creatinine clearance, such as e.g. mild, moderate or severe renal impairment, or end stage renal disease) and/or who are at risk of developing renal complications, e.g. patients with or at risk of diabetic nephropathy (including e.g. chronic and progressive renal insufficiency, albuminuria and/or proteinuria).

The dose of linagliptin when administered orally is 0.5 mg to 10 mg per patient per day, preferably 2.5 mg to 10 mg or 1 mg to 5 mg per patient per day.

For example, the daily oral amount 5 mg linagliptin may be given in an once daily dosing regimen (i.e. 5 mg linagliptin once daily) or in a twice daily dosing regimen (i.e. 2.5 mg linagliptin twice daily).

Further, the present invention relates to a pharmaceutical composition according to this invention for use in a method of treating type 2 diabetes, said method comprising the oral administration of said composition containing effective amounts of the active ingredients (such as e.g. 5mg/15mg, 5mg/30mg or 5mg/45mg of linagliptin/pioglitazone) preferably once daily to the patient in need thereof.

The present invention is not to be limited in scope by the specific embodiments described herein. Various modifications of the invention in addition to those described herein may become apparent to those skilled in the art from the present disclosure. Such modifications are intended to fall within the scope of the appended claims.

All patent applications cited herein are hereby incorporated by reference in their entireties.

Further embodiments, features and advantages of the present invention may become apparent from the following examples. The following examples serve to illustrate, by way of example, the principles of the invention without restricting it.

- 30 -

Examples1a. Composition of BI 1356 + Pioglitazone HCl FDC 5/15 mg Bilayer Tablet

Material	rel. Mass %	mg / Dosage unit
Pioglitazone HCl	4.5917	16.530
Mannitol	32.4083	116.670
Cellulose microcrystalline	10.0000	36.000
Copovidone	1.0000	3.600
Crospovidone	1.0000	3.600
Sodium stearyl fumarate	1.0000	3.600
Sum pioglitazone layer		180.000
Linagliptin	1.3889	5.000
Mannitol	36.3611	130.900
Pregelatinized starch	5.0000	18.000
Maize starch	5.0000	18.000
Copovidone	1.5000	5.400
Magnesium stearate	0.7500	2.700
Sum linagliptin layer		180.000
Sum tablet cores	100.000	360.000
Hydroxypropylmethylcellulose	50.000	5.000
Propylene glycol	5.000	0.500
Titan dioxide	24.000	2.400
Talc	20.000	2.000
Iron oxide, yellow	1.000	0.100
Iron oxide, red	-	-
Water, purified		
Sum Coating	100.000	10.000
Sum Filmtablets		370.0

- 31 -

1b. Composition of BI 1356 + Pioglitazone HCl FDC 5/30 mg Bilayer Tablet

Material	rel. Mass %	mg / Dosage unit
Pioglitazone HCl	9.1833	33.0600
Mannitol	27.8167	100.1400
Cellulose microcrystalline	10.0000	36.0000
Copovidone	1.0000	3.6000
Crospovidone	1.5000	5.4000
Sodium stearyl fumarate	1.5000	5.4000
Sum pioglitazone layer		180.0000
Linagliptin	1.3889	5.0000
Mannitol	36.3611	130.9000
Pregelatinized starch	5.0000	18.0000
Maize starch	5.0000	18.0000
Copovidone	1.5000	5.4000
Magnesium stearate	0.7500	2.7000
Sum linagliptin layer		180.0000
Sum tablet cores	100.0000	360.0000
Hydroxypropylmethylcellulose	50.0000	5.0000
Propylene glycol	5.0000	0.5000
Titan dioxide	21.0000	2.1000
Talc	20.0000	2.0000
Iron oxide, yellow	3.7500	0.3750
Iron oxide, red	0.2500	0.0250
Water, purified		
Sum Coating	100.0000	10.0000
Sum Filtablets		370.0000

- 32 -

1c. Composition of BI 1356 + Pioglitazone HCl FDC 5/45 mg Bilayer Tablet

Material	rel. Mass %	mg / Dosage unit
Pioglitazone HCl	11.0200	49.5900
Mannitol	33.3800	150.2100
Cellulose microcrystalline	12.0000	54.0000
Copovidone	1.2000	5.4000
Crospovidone	1.2000	5.4000
Sodium stearyl fumarate	1.2000	5.4000
Sum pioglitazone layer		270.0000
Linagliptin	1.1111	5.0000
Mannitol	29.0889	130.9000
Pregelatinized starch	4.0000	18.0000
Maize starch	4.0000	18.0000
Copovidone	1.2000	5.4000
Magnesium stearate	0.6000	2.7000
Sum linagliptin layer		180.0000
Sum tablet cores	100.0000	450.0000
Hydroxypropylmethylcellulose	50.0000	6.0000
Propylene glycol	5.0000	0.6000
Titan dioxide	21.0000	2.5200
Talc	20.0000	2.4000
Iron oxide, yellow	2.0000	0.2400
Iron oxide, red	2.0000	0.2400
Water, purified		
Sum Coating	100.0000	12.0000
Sum Filmtablets		462.0000

- 33 -

1a'. Alternative composition of BI 1356 + Pioglitazone HCl FDC 5/15 mg Bilayer Tablet

Material	mg / Dosage unit 5/15 mg tablet
Pioglitazone HCl	16.53
Mannitol	50.07
Cellulose microcrystalline	18.00
Copovidone	1.80
Crospovidone	1.80
Sodium stearyl fumarate	1.80
Sum pioglitazone layer	90.00
Linagliptin	5.00
Mannitol	130.90
Pregelatinized starch	18.00
Maize starch	18.00
Copovidone	5.40
Magnesium stearate	2.70
Sum linagliptin layer	180.00
Sum tablet cores	270.00
Hydroxypropylmethylcellulose	4.00
Propylene glycol	0.40
Titan dioxide	1.99
Talc	1.60
Iron oxide, yellow	0.01
Iron oxide, red	-
Water, purified	
Sum Coating	8.00
Sum Filmtablets	278.0

- 34 -

1". Alternative composition of BI 1356 + Pioglitazone FDC Bilayer Tablets

Qualitative and quantitative composition:

Dosage strength Linagliptin / Pioglitazone	5 mg / 15 mg		5 mg / 30 mg		5 mg / 45 mg	
Ingredients	[mg per film-coated tablet]	(%)	[mg per film-coated tablet]	(%)	[mg per film-coated tablet]	(%)
Linagliptin	5.0000	2.7778	5.0000	2.7778	5.0000	2.7778
Mannitol	130.9000	72.7222	130.9000	72.7222	130.9000	72.7222
Starch, pregelatinized	18.0000	10.0000	18.0000	10.0000	18.0000	10.0000
Maize starch	18.0000	10.0000	18.0000	10.0000	18.0000	10.0000
Copovidone	5.4000	3.0000	5.4000	3.0000	5.4000	3.0000
Magnesium stearate	2.7000	1.5000	2.7000	1.5000	2.7000	1.5000
Subtotal Linagliptin Layer	180.0000	100.0000	180.0000	100.0000	180.0000	100.0000
Pioglitazone hydrochloride	16.5300	18.3667	33.0600	18.3667	49.5900	18.3667
Mannitol	50.0700	55.6333	100.1400	55.6333	150.2100	55.6333
Cellulose, microcrystalline	18.0000	20.0000	36.0000	20.0000	54.0000	20.0000
Copovidone	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Crospovidone	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Sodium stearyl fumarate	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Subtotal Pioglitazone Layer	90.0000	100.0000	180.0000	100.0000	270.0000	100.0000
Opadry yellow	8.0000	100.0000	-	-	-	-
Opadry orange	-	-	10.0000	100.0000	-	-
Opadry pink	-	-	-	-	12.0000	100.0000
Subtotal Filmcoat	8.0000	100.0000	10.0000	100.0000	12.0000	100.0000
Total weight Film-coated Tablet	278.0000	100.0000	370.0000	100.0000	462.0000	100.0000

Qualitative and quantitative composition of Opadry® yellow, Opadry® orange and Opadry® pink film coat for linagliptin / pioglitazone film-coated tablets:

Ingredient	Quantity [% w/w]			Function
	Opadry® yellow	Opadry® orange	Opadry® pink	
Hypromellose 2910	50.0000	50.0000	50.0000	Film-forming agent
Titanium dioxide	24.8500	21.0000	21.0000	Pigment
Talc	20.0000	20.0000	20.0000	Anti-adherent
Propylene glycol	5.0000	5.0000	5.0000	Plasticizer
Iron oxide, yellow	0.1500	3.7500	2.0000	Pigment
Iron oxide, red	---	0.2500	2.0000	Pigment
Total	100.0000	100.0000	100.0000	---

5

Manufacturing process of the exemplary compositions:

a) Linagliptin final blend:

10 i.) Granulation liquid for linagliptin final blend (step 1):

Copovidone is dispensed in water, purified.

ii.) Granulate for linagliptin final blend (step 2):

Mannitol, starch, pregelatinized and maize starch are screened through a suitable screen

15 and pre-mixed in an appropriate high-shear mixer altogether with linagliptin, which has been optionally screened through a suitable screen.

Alternatively, mannitol, pregelatinized starch, maize starch and linagliptin are screened through a suitable screen and pre-mixed in an appropriate high-shear mixer.

20 Preferably the screening machine is directly linked to the granulator and the materials are directly screened into the granulator. Optionally the material transfer into the granulator and the screening step are combined using vacuum transfer via the screen into the granulator. In

- 36 -

any case linagliptin is preferably screened in between the other excipients, less preferably before or after the excipients.

The pre-mix is moistened with the granulation liquid and granulated using an appropriate high-shear mixer. The wet granulate is optionally wet screened through a suitable screen.

5 Subsequently, the wet granulate is dried in a fluid bed dryer and consecutively screened through a suitable screen; optionally, the screened granulate may be blended in an appropriate free-fall blender.

Alternatively a screening step takes place during drying, for which the drying process is paused and continued after screening. Subsequently, the dried granulate is optionally

10 screened a second time followed by an optional blending step in an appropriate blender such as a free fall blender.

iii.) Linagliptin final blend (step 3):

For the linagliptin final blend optionally either fractions or multiples of entire linagliptin

15 granulate batches are combined without impact on the quality and manufacturability of the drug product.

Pre-screened magnesium stearate is added to the screened and optionally blended granulate and subsequently final blending is performed in an appropriate free-fall blender.

20 b) Pioglitazone final blend:

i.) Granulation liquid for pioglitazone final blend (step 4):

Copovidone is dispensed in water, purified.

25 ii.) Granulate for pioglitazone final blend (step 5):

Pioglitazone hydrochloride, mannitol and cellulose (microcrystalline; e.g. a part or entire amount thereof) are screened through a suitable screen and pre-mixed in an appropriate high-shear mixer. The pre-mix is moistened with the granulation liquid and granulated using an appropriate high-shear mixer. The wet granulate is optionally wet screened through a

30 suitable screen. Subsequently, the wet granulate is dried in a fluid bed dryer and consecutively screened through a suitable screen;

subsequently, the screened granulate may be blended in an appropriate free-fall blender.

iii.) Pioglitazone final blend (step 6):

- 37 -

For the pioglitazone final blend optionally either fractions or multiples of entire pioglitazone granulate batches are combined without impact on the quality and manufacturability of the drug product;

To obtain the pioglitazone final blend:

5 Variant 1: crospovidone and sodium stearyl fumarate are pre-blended and screened and consecutively combined with the screened pioglitazone granulate to perform the final blending; or

Variant 2: Cellulose (microcrystalline; e.g. remaining part thereof), crospovidone and sodium stearyl fumarate are pre-blended and screened and consecutively combined with the
10 screened pioglitazone granulate to perform the final blending; or

Variant 3: Cellulose (microcrystalline; e.g. remaining part thereof), crospovidone and sodium stearyl fumarate are combined with the screened and optionally blended pioglitazone granulate to perform a blending step. Consecutively the blend is screened and final blending takes place.

15 All screening and pre-/final-blending process steps are performed using suitable screens and appropriate free-fall blenders, respectively;

Optionally, part of the microcrystalline cellulose (e.g. 30-40% of total amount thereof, such as e.g. about 34%) may present in the pioglitazone granulate and the remaining part thereof
20 (e.g. 60-70% of total amount thereof, such as e.g. about 66%) may be present in the extragranular portion of the final blend. The ratio of the intragranular microcrystalline cellulose to the extragranular microcrystalline cellulose may be from about 1:4 to about 1:1, preferably from about 1:3 to about 1:1, more preferably from about 1:2.5 to about 1.15, even more preferably from about 3:7 to about 4:6, most preferably about 1:2.

25

c) Linagliptin / pioglitazone bilayer tablet cores (step 7):

The pioglitazone final blend and the linagliptin final blend are compressed into bilayer tablet cores using a standard bilayer rotary tablet press;

30

d) Film-coating suspension (step 8):

Hydromellose (HPMC), talc, propylene glycol, titanium dioxide, iron oxide yellow and/or, depending on the dosage strength, iron oxide red are dispersed in water, purified to achieve
35 an aqueous film-coating suspension; or alternatively a commercially available premixture

- 38 -

such as Opadry® of identical qualitative and quantitative composition is used instead of the single film ingredients. Depending on dosage strength Opadry® yellow, Opadry® orange or Opadry® pink is dispersed in purified water to obtain an aqueous film-coating suspension).

5 e) Linagliptin / pioglitazone film-coated tablets (step 9):

The linagliptin / pioglitazone bilayer tablet cores are coated with the film-coating suspension in a drum coater to produce linagliptin / pioglitazone film-coated tablets. Preferably a perforated drum coater is used.

10

1. Formulation variant with extragranular excipient in the pioglitazone-containing part or layer

15 Qualitative and quantitative composition:

Dosage strength	15 mg		30 mg		45 mg	
Pioglitazone						
Ingredients	[mg per film-coated tablet]	(%)	[mg per film-coated tablet]	(%)	[mg per film-coated tablet]	(%)
Pioglitazone hydrochloride	16.5300	18.3667	33.0600	18.3667	49.5900	18.3667
Mannitol	50.0700	55.6333	100.1400	55.6333	150.2100	55.6333
Cellulose, microcrystalline	6.0000	6.6667	12.0000	6.6667	18.0000	6.6667
Copovidone	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Subtotal granulate	74.4000	82.6667	148.8000	82.6667	223.2000	82.6667
Cellulose, microcrystalline	12.0000	13.3333	24.0000	13.3333	36.0000	13.3333
Crospovidone	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Sodium stearyl fumarate	1.8000	2.0000	3.6000	2.0000	5.4000	2.0000
Total Pioglitazone Part	90.0000	100.0000	180.0000	100.0000	270.0000	100.0000

Copovidone is dissolved in purified water to produce a granulation liquid. Pioglitazone hydrochloride, mannitol and a part of microcrystalline cellulose are screened through a suitable screen and blended in a suitable mixer (e.g. high-shear mixer) to produce a pre-mix.

- 5 The pre-mix is moistened with the granulation liquid and subsequently granulated (e.g. using a suitable high-shear mixer). The wet granulate is optionally wet sieved through a suitable sieve. Subsequently, the wet granulate is dried in a fluid bed dryer and consecutively screened through a suitable screen; subsequently, the screened granulate may be blended in an appropriate free-fall blender.
- 10 The remaining part of microcrystalline cellulose, crospovidone and sodium stearyl fumarate are added extragranular to the screened and optionally blended granulate to perform a blending step. Consecutively the blend is screened and final blending takes place in a suitable blender to produce the final blend.

15

2. Composition of BI 1356 + Pioglitazone HCl FDC Bilayer Tablet (with the variant pregelatinized starch as second diluent)

Material	mg / Dosage unit 5/15 mg	mg / Dosage unit 5/30 mg	mg / Dosage unit 5/45 mg
Pioglitazone HCl	16.53	33.06	49.59
Mannitol	109.47	101.94	152.91
Pregelatinized starch	45.00	36.00	54.00
Copovidone	3.60	3.60	5.40
Crospovidone	1.80	1.80	2.70
Sodium stearyl fumarate	3.60	3.60	5.40
Sum pioglitazone layer	180.00	180.00	270.00
Linagliptin	5.00	5.00	5.00
Mannitol	130.90	130.90	130.90
Pregelatinized starch	18.00	18.00	18.00
Maize starch	18.00	18.00	18.00
Copovidone	5.40	5.40	5.40
Magnesium stearate	2.70	2.70	2.70
Sum linagliptin layer	180.00	180.00	180.00

- 40 -

Sum tablet cores	360.00	360.00	450.00
Hydroxypropylmethylcellulose	5.00	5.00	6.00
Propylene glycol	0.50	0.50	0.60
Titan dioxide	2.40	2.10	2.52
Talc	2.00	2.00	2.40
Iron oxide, yellow	0.10	0.375	0.24
Iron oxide, red	-	0.025	0.24
Water, purified			
Sum Coating	10.000	10.000	12.000
Sum Filmtablets	370.0	370.0	462.0

This composition and tablet is prepared by a similar or analogous process as that described herein for the variants with microcrystalline cellulose as second diluent.

5

3. Lubricant selection for optimization:

Sodium stearyl fumarate is preferred over magnesium stearate as lubricant, e.g. since it does not show some disadvantages found for magnesium stearate for over blending and/or reduction of dissolution of active ingredients (APIs). Rather sodium stearyl fumarate shows with sieving step and longer blending time of pioglitazone granulate and lubricant, increasing dissolution rate for pioglitazone.

For example, with the use of magnesium stearate (compared to the use of sodium stearyl fumarate) up to 25 % less dissolution of pioglitazone after 5 minutes, 19 % less dissolution of pioglitazone after 10 minutes, 15 % less dissolution of pioglitazone at 15 minutes and/or not 100 % receivable dissolution of pioglitazone at 45 minutes at pH2 with 50 UpM is found. Dissolution-Medium: pH 2,0: 0,01 M HCl / 0,3 M KCl; Paddle, 900 mL, 50 rpm, 37,0 °C.

For further example, with reduction of sodium stearyl fumarate from 2 % by weight to e.g. 1 % by weight of the pioglitazone layer, decreasing of dissolution of pioglitazone of 10 - 20 % (and more) at pH 2 at 50 Upm in vitro is found. The amount of sodium stearyl fumarate is preferably ≥ 1 % by weight of the pioglitazone layer, e.g. 1-3% or 1-2%, more preferably ≥ 1.2 %, e.g from 1.2 % to 2 %, most preferably about 2%, by weight of the pioglitazone layer.

25

4. Comparison of bilayer tablet and monolayer tablet in view of stability results:

a) Composition of monolayer tablet:

Material:	mg / Dosage unit
Linagliptin	5
Pioglitazone HCl, unmilled	49.59
Mannitol fine	40
Mannitol M 200	165.96
Crospovidone	5.4
Magnesium stearate	4.05

5

b) Composition of bilayer tablet:

Material Layer1:	mg / Dosage unit
Pioglitazone HCl	49.59
Mannitol fine	22.7
Mannitol M 200	188.26
Crospovidone	5.4
Magnesium stearate	4.05

Material Layer2:	mg / Dosage Unit
Linagliptin	5
Mannitol fine	62.95
Pregelatinized starch	9
Maize starch undried	9
Copovidone	2.7
Magnesium stearate	1.35

10 Stability results (40°C, 75% rh, open, after 4 - 6 week):

Version a) monolayer tablet (film coated, 5/45mg):

- degradation after 4 weeks: linagliptin about 11%, pioglitazone <0.2%

Version b) bilayer tablet (film coated, 5/45mg with roller compaction layer of pioglitazone):

- degradation after 6 weeks: linagliptin <0.2%, pioglitazone <0.2%

15

20

- 42 -

5. Stability / assay results of Example 1c (5/45 mg film coated tablet):

Assay results: linagliptin 102.1%, pioglitazone 99.2% at start

5 Dissolution results (Q at 15 min, pH 2.0): linagliptin 102%, pioglitazone 95%

Dissolution profile pioglitazone:

10 min: 92%, 15 min: 95%, 30 min: 97%, 45 min 97%

Dissolution profile linagliptin:

10 10 min: 100%, 15 min: 102%, 30 min: 103%, 45 min 103%

Stability results (40°C, 75% rh, open, after 4 week):

- degradation: linagliptin about 0.1%, pioglitazone <0.1%,

- assay: linagliptin 101.2%, pioglitazone 99.5%

15

Stability results (40°C, 75% rh, open, after 9 week):

- degradation: linagliptin about 0.4%, pioglitazone <0.1%,

- assay: linagliptin 99.5%, pioglitazone 99.0%

20

Claims

1. A pharmaceutical composition comprising
a first part, composition or layer comprising pioglitazone, particularly pioglitazone
5 hydrochloride, and one or more excipients, and
a second part, composition or layer comprising linagliptin and one or more excipients.
2. The composition of claim 1, wherein the first part, composition or layer comprises
pioglitazone hydrochloride, the first diluent mannitol, the second diluent microcrystalline
10 cellulose, the binder copovidone, the disintegrant crospovidone, and the lubricant sodium
stearyl fumarate.
3. The composition of claim 1 or 2, wherein the second part, composition or layer comprises
linagliptin, the first diluent mannitol, the second diluent pregelatinized starch, the binder
15 copovidone, the disintegrant corn starch, and the lubricant magnesium stearate.
4. The composition of claim 1, 2 or 3 in solid oral dosage form, e.g. in the form of a capsule,
a tablet or a film-coated tablet.
- 20 5. The composition of claim 1, 2, 3 or 4, in the form of a bilayer tablet.
6. The composition of claim 5, which is a film-coated bilayer tablet.
7. The composition of claim 6, wherein the film-coat comprises hydroxypropylmethylcellulose
25 (HPMC), polypropylene glycol, talc, titanium dioxide and an iron oxide.
8. The composition of any one of claims 1 to 7, wherein pioglitazone, optionally in the form of
its hydrochloride salt, is present in an amount of 15 mg, 30 mg or 45 mg based on the weight
of pioglitazone.
30
9. The composition of any one of claims 1 to 8, wherein linagliptin is present in an amount of
5 mg.
10. The composition of any one of claims 1 to 8, wherein linagliptin is present in an amount
35 of 2.5 mg.

- 44 -

11. The composition of any one claims 1 to 10, wherein the first part, composition or layer comprises

an intragranular portion containing pioglitazone hydrochloride, the first diluent mannitol, a partial amount of the second diluent microcrystalline cellulose, and the binder copovidone; and

an extragranular portion containing the disintegrant crospovidone, the lubricant sodium stearyl fumarate, and the remaining partial amount of the second diluent microcrystalline cellulose.

12. The composition of claim 11, wherein the amount of the microcrystalline cellulose contained in the intragranular portion is from 10 to 80%, more preferably from 20 to 50%, most preferably from 30 to 40%, of total amount of microcrystalline cellulose comprised in the first part, composition or layer.

13. The composition of claim 11 or of claim 12, wherein the amount of the microcrystalline cellulose contained in the extragranular portion is from 20 to 90%, more preferably from 50 to 80%, most preferably from 60 to 70%, of total amount of microcrystalline cellulose comprised in the first part, composition or layer.

14. The composition of claim 11, 12 or 13, wherein from 30% to 40% of the total amount of microcrystalline cellulose is present intragranular, and wherein from 60% to 70% of the total amount of microcrystalline cellulose is present extragranular.

15. The composition of claim 11, 12, 13 or 14, wherein the ratio of intragranular microcrystalline cellulose to extragranular microcrystalline cellulose is about 1:2.

16. A process for the preparation of the first part, composition or layer of a pharmaceutical composition according to any one of claims 1 to 15, said process comprising

- a. dissolving a binder in a solvent to produce a granulation liquid,
- b. blending pioglitazone hydrochloride (pioglitazone HCl), a first diluent, and a part of a second diluent to produce a pre-mix,
- c. moistening and granulating the pre-mix with the granulation liquid,
- d. optionally wet sieving, drying and dry sieving of the obtained pioglitazone-containing granulate,

- 45 -

e. combining the pioglitazone-containing granulate with a lubricant, a disintegrant, and the remaining part of the second diluent for final blending.

17. A process for the preparation of the second part, composition or layer of a

5 pharmaceutical composition according to any one of claims 1 to 15, said process comprising

a. dissolving a binder in a solvent to produce a granulation liquid,

b. blending linagliptin, a first diluent, a second diluent, and a disintegrant to produce a pre-mix,

c. moistening and granulating the pre-mix with the granulation liquid,

10 d. optionally wet sieving, drying and dry sieving of the obtained linagliptin-containing granulate,

e. adding a lubricant to the linagliptin-containing granulate for final blending.

18. A process for the preparation of a pharmaceutical composition according to any one of

15 claims 1 to 15, said process comprising the process of claim 16 and the process of claim 17, and further comprising

combining the pioglitazone final blend obtained in step e. of claim 16 and the linagliptin final blend obtained in step e. of claim 17 and compressing the blends into a bilayer tablet core, and, optionally,

20 preparing a coating suspension, and

coating the tablet core with the coating suspension to produce a film-coated bilayer tablet.

19. The composition of any one claims 1 to 18 for use in treating type 2 diabetes or obesity.

25 20. The composition of any one claims 1 to 19 for use in a method of treating type 2

diabetes, said method comprising the oral administration of the composition once or twice daily to the patient.

30

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/057163

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K9/20 A61K31/4439 A61K31/522 A61P5/48
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/121945 A2 (BOEHRINGER INGELHEIM INT [DE]; FRIEDL THOMAS [DE]; BRAUN MICHAEL [DE];) 8 October 2009 (2009-10-08)	1,4
Y	claims	1-20
Y	WO 2008/093882 A1 (TAKEDA PHARMACEUTICAL [JP]; NAKAMURA KENJI [JP]; KIYOSHIMA KENICHIRO []) 7 August 2008 (2008-08-07)	1-20
Y	claims; examples	1-20
Y	WO 2006/047248 A1 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; BURKEY BRYAN [US]; HUGHES) 4 May 2006 (2006-05-04)	1-20
	claims 8,9	
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--	--

Date of the actual completion of the international search 17 June 2011	Date of mailing of the international search report 27/06/2011
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Zimmer, Barbara
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/057163

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2006/135693 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; KOWALSKI JAMES [US]; LAKS) 21 December 2006 (2006-12-21) examples -----	1-20
Y	WO 2010/043688 A1 (BOEHRINGER INGELHEIM INT [DE]; GRAEFE-MODY EVA ULRIKE [DE]; KLEIN THOM) 22 April 2010 (2010-04-22) pages 32,36; claims -----	1-20
Y	EP 1 852 108 A1 (BOEHRINGER INGELHEIM PHARMA [DE]) 7 November 2007 (2007-11-07) examples -----	1-20
X,P	WO 2010/092125 A1 (BOEHRINGER INGELHEIM INT [DE]; EICKELMANN PETER [DE]; MARK MICHAEL [DE]) 19 August 2010 (2010-08-19) page 50, paragraph 2 -----	1-20
X,P	WO 2010/092163 A2 (BOEHRINGER INGELHEIM INT [DE]; GRAEFE-MODY EVA ULRIKE [DE]; WOERLE HAN) 19 August 2010 (2010-08-19) table 1 -----	1-20
X,P	WO 2011/039367 A2 (BOEHRINGER INGELHEIM INT [DE]; MEINICKE THOMAS [DE]) 7 April 2011 (2011-04-07) claim 7 -----	1-20
X,P	WO 2010/147768 A1 (MERCK SHARP & DOHME [US]; BIRNINGER NICHOLAS [US]; JOHN CHRISTOPHER T) 23 December 2010 (2010-12-23) claims -----	1-20
Y	THOMAS LEO ET AL: "(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, WILLIAMS AND WILKINS CO, vol. 325, no. 1, 1 April 2008 (2008-04-01), pages 175-182, XP009105508, ISSN: 0022-3565, DOI: DOI:10.1124/JPET.107.135723 abstract -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/057163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2009121945	A2	08-10-2009	AR 071175 A1	02-06-2010
			AU 2009232043 A1	08-10-2009
			CA 2720450 A1	08-10-2009
			CN 101983073 A	02-03-2011
			CO 6251277 A2	21-02-2011
			EC SP10010489 A	30-10-2010
			EP 2285410 A2	23-02-2011
			KR 20110005690 A	18-01-2011
			PE 17302009 A1	10-12-2009
			UY 31747 A	10-11-2009
WO 2008093882	A1	07-08-2008	AR 065097 A1	13-05-2009
			AT 488227 T	15-12-2010
			AU 2008211981 A1	07-08-2008
			CA 2677201 A1	07-08-2008
			CL 2792008 A1	18-08-2008
			CN 101646420 A	10-02-2010
			DK 2107905 T3	31-01-2011
			EA 200970726 A1	26-02-2010
			EC SP099608 A	29-09-2009
			EP 2107905 A1	14-10-2009
			ES 2354397 T3	14-03-2011
			HR 20110094 T1	31-03-2011
			JP 2010517937 T	27-05-2010
			MA 31169 B1	01-02-2010
			PE 16632008 A1	25-12-2008
			PT 2107905 E	17-12-2010
			SI 2107905 T1	31-03-2011
US 2010092551 A1	15-04-2010			
ZA 200905621 A	27-10-2010			
WO 2006047248	A1	04-05-2006	AU 2005299808 A1	04-05-2006
			AU 2009222515 A1	22-10-2009
			BR PI0518409 A2	18-11-2008
			CA 2581298 A1	04-05-2006
			CN 101035522 A	12-09-2007
			EP 1807066 A1	18-07-2007
			JP 2008517921 T	29-05-2008
			KR 20070068407 A	29-06-2007
US 2009253752 A1	08-10-2009			
WO 2006135693	A2	21-12-2006	AR 054382 A1	20-06-2007
			AU 2006258013 A1	21-12-2006
			AU 2010212516 A1	16-09-2010
			BR PI0613567 A2	18-01-2011
			CA 2610412 A1	21-12-2006
WO 2006135693	A2		EP 1893236 A2	05-03-2008
			GT 200600218 A	28-03-2007
			JP 2008543767 T	04-12-2008
			KR 20080018257 A	27-02-2008
			PE 01652007 A1	09-03-2007
US 2008193529 A1	14-08-2008			
WO 2010043688	A1	22-04-2010	AR 073876 A1	09-12-2010
			AU 2009305419 A1	22-04-2010
			CA 2738367 A1	22-04-2010
			UY 32177 A	31-05-2010

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/057163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1852108	A1	07-11-2007	
		AR 060755 A1	10-07-2008
		AT 480228 T	15-09-2010
		AU 2007247193 A1	15-11-2007
		BR PI0711179 A2	03-05-2011
		CA 2649922 A1	15-11-2007
		CN 101437493 A	20-05-2009
		DK 2023902 T3	15-11-2010
		EA 200802184 A1	30-06-2009
		EC SP088800 A	27-11-2008
		EP 2023902 A1	18-02-2009
		EP 2277509 A1	26-01-2011
		EP 2283819 A1	16-02-2011
		WO 2007128724 A1	15-11-2007
		ES 2348576 T3	09-12-2010
		HR 20100507 T1	31-10-2010
		JP 2009535376 T	01-10-2009
		KR 20090009226 A	22-01-2009
		PE 06982008 A1	04-08-2008
		PT 2023902 E	12-10-2010
		RS 51466 B	30-04-2011
		SI 2023902 T1	31-01-2011
		US 2008107731 A1	08-05-2008
		UY 30319 A1	02-01-2008
		ZA 200808361 A	27-10-2010
WO 2010092125	A1	19-08-2010	
		AR 075421 A1	30-03-2011
		US 2011046076 A1	24-02-2011
		UY 32441 A	30-09-2010
WO 2010092163	A2	19-08-2010	NONE
WO 2011039367	A2	07-04-2011	NONE
WO 2010147768	A1	23-12-2010	NONE